Liver Embolization Clinical Trials

Clinical trials related to Liver Embolization Procedure

Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma Through Image-guided Locoregional Therapy

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

Trans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC). TACE is a minimally invasive procedure that involves placing a catheter into the artery in the liver that feeds the tumor, administering chemotherapeutics and then blocking the artery with embolics in order to kill tumor cells by depriving them of essential oxygen and nutrients. While TACE has a proven survival benefit, local recurrence is common, and long-term survival rates are poor. Prior studies demonstrate that HCC cells survive the oxygen and nutrient deprivation through autophagy, a process of cellular self-eating, to provide nutrients required for survival. The proposed project will leverage this dependency to develop a novel approach to TACE that integrates autophagy inhibition to improve therapeutic response by increasing tumor cell killing and enhancing anti-tumor immunity.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Male or female, aged 18 years, meeting criteria for diagnosis of BCLC B HCC and referred to undergo TACE

• HCC measuring 3 cm in minimum transverse diameter and meets LI-RADS 5 criteria based on cross-sectional imaging as determined by a board-certified, sub-specialty trained radiologist

• Childs Pugh Turcotte A/B7, Performance Status 0

• Informed of investigational nature of this study with provision of signed and dated informed consent form

• Stated willingness to comply with all study procedures and availability for the duration of the study

Locations
United States
Pennsylvania
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
RECRUITING
Philadelphia
Contact Information
Primary
Terence P Gade, MD PhD
Terence.Gade@va.gov
(215) 823-5800
Time Frame
Start Date: 2026-04-01
Estimated Completion Date: 2030-10-15
Participants
Target number of participants: 93
Treatments
Experimental: Transarterial Embolization with Hydroxychloroquine
Intra-arterial hydroxychloroquine in Lipiodol + transarterial embolization followed by oral hydroxychloroquine
Placebo_comparator: Transarterial Embolization without Hydroxychloquine
Intra-arterial Lipiodol + transarterial embolization followed by oral placebo
Related Therapeutic Areas
Sponsors
Leads: VA Office of Research and Development

This content was sourced from clinicaltrials.gov

Similar Clinical Trials